Objective: We previously reported that oral administration of the selective cyclooxygenase-2 (COX-2) inhibitor etodolac results in antitumor effects in endometrial cancer tissue. Herein, we investigated whether these antitumor effects could be assessed using endometrial cytological findings. Study Design: Etodolac (400 mg b.i.d. for 2 weeks) was administered preoperatively to 21 endometrial cancer patients: 16 had COX-2-positive disease and 5 had COX-2-negative disease. Twenty-one pairs of pre- and post-etodolac-treatment endometrial cytological samples were collected to review changes in the cytological features. Results: In the COX-2-positive patients, nuclear atypia was slightly decreased in 3 of the 16 cases, while the mitotic index was decreased in all cases. Cellular overlapping and tumor cell cluster outlines were somewhat affected in 6 and 8 cases, respectively. Nuclear/cytoplasmic ratio, anisokaryosis and hyperchromasia were also reduced in 6, 4, and 2 cases, respectively; however, tumor diathesis and nucleoli features were unchanged. In contrast, endometrial cytological features did not appear to be affected in the 5 COX-2-negative patients. Conclusions: We conclude that the antitumor effects observed in endometrial cancer tissues following oral administration of etodolac are reflected in and can be easily assessed by evaluating endometrial cytological features.

Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, et al: Expression of cyclooxygenase-2 (COX-2) in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 2005;26:1419–1428.
Uotila PJ, Erkkola RU, Klemi PJ: The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann Med 2002;34:428–433.
Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K: Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002;33:213–219.
Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, Dubois RN, et al: Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000;2:483–490.
Farrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, et al: Cyclooxygenase-2 expression in endometrial carcinoma – correlation with clinicopathological parameter and clinical outcome. Cancer 2002;95:801–807.
Uefuji K, Ichikura T, Shinomiya N, Mochizuki H: Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res 2000;20:4279–4284.
Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induced apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767–5772.
Li M, Lotan R, Levin B, Tahara E, Lippman SM, Xu XC: Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000;9:545–549.
Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M, et al: Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 2001;30:41–47.
Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeff SK, et al: Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitors, NS-398. Cancer Res 2000;60:4926–4931.
Tsubouchi Y, Mukai S, Kawahito Y, Yamada R, Kohno M, Inoue K, et al: Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000;20:2867–2872.
Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356–4362.
Genç S, Attar E, Gürdöl F, Kendigelen S, Bilir A, Serdaroğlu H: The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture. Clin Exp Med 2007;7:6–10.
Wood NJ, Quinton NA, Burdall S, Sheridan E, Duffy SR: Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. Int J Gynecol Cancer 2007;17:447–454.
Kanayama S, Yamada Y, Kawaguchi R, Tsuji Y, Haruta S, Kobayashi H: Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. Oncol Rep 2008;19:117–122.
Hasegawa K, Torii Y, Ishii R, Oe S, Kato R, Udagawa Y: Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch Gynecol Obstet 2011;284:1515–1521.
Detre S, Saclani Jotti G, Dowsett M: A ‘quickscore’ method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876–878.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.
Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al: A randomized, double blinded, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857–860.
Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, et al: Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 2010;126:1467–1473.
Altorki NK, Keresztes JL, Port JL, Libby DM, Korst RJ, Flieder DB et al: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645–2650.
Aruajo AM, Mendez JC, Coelho AL, Sousa B, Barata F, Figueiredo A, et al: Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Inv 2009;27:391–396.
Shinohara N, Kumagai A, Kanagawa K, Maruyama S, Abe T, Sazawa A, Nonomura K: Multicenter phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon-α for metastatic renal cell carcinoma. Jpn J Clin Oncol 2009;39:720–729.
Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S: Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 2010;44:286–288.
Debucquoy A, Roels S, Goethals L, Libbrecht L, Culsem EV, Geboes K, et al: Double blind randomized phase II study with radiation + 5-fluorouracil ± celecoxib for resectable rectal cancer. Radiother Oncol 2009;93:273–278.
Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, et al: A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009;29:1483–1488.
Koch A, Gustafsson B, Fohlin H, Sörenson S: Cyclooxygenase-2 expression in lung cancer cells evaluated by immunocytochemistry. Diagn Cytopathol 2011;39:188–193.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.